BioXcel Therapeutics (BTAI) Operating Expenses (2017 - 2026)

BioXcel Therapeutics' Operating Expenses history runs 10 years deep, the most recent figure standing at $10.4 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 1.58% year-over-year to $10.4 million in Q1 2026; TTM through Mar 2026 was $51.3 million, a 6.85% decrease from a year earlier, with the FY2025 full-year figure at $51.1 million, down 26.48% from the prior year.
• Operating Expenses eased to $10.4 million in Q1 2026 per BTAI's latest filing, from $10.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $53.1 million in Q4 2022 and bottomed at $10.3 million in Q1 2025.
• The 5-year median for Operating Expenses is $20.3 million (2023), against an average of $27.3 million.
• Across the five-year window, Operating Expenses jumped 103.33% in 2022 and slumped 68.12% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $53.1 million in 2022, then slumped by 61.89% to $20.3 million in 2023, then tumbled by 46.38% to $10.9 million in 2024, then declined by 2.96% to $10.5 million in 2025, then dropped by 1.03% to $10.4 million in 2026.
• Per Business Quant, the three latest BTAI Operating Expenses figures stand at $10.4 million (Q1 2026), $10.5 million (Q4 2025), and $14.3 million (Q3 2025).